Journal articleSignal Transduct Target Ther2024
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
- Journal
- Signal Transduct Target Ther
- Published
- 19 September 2024
- Citations
- 19
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Trials 1
- Its registry lists this paper as resultsIrinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancre… NCT05074589↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.